We are delighted to inform you that our results on the GAIN-2 trial has been published in European Journal of Cancer
The GAIN-2 trial was designed to identify a superior intense dose-dense strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed.
Conclusion: iDFS is equal in both regimens, but tailoring dose-dense chemotherapy improved outcomes in HR+/HER2-, lobular cancer and patients ≤50 years.
Möbus V, Lück HJ, Ladda E, et al. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer. 2021;156:138-148.